Biomarkers of myocardial injury with different energy sources for atrial fibrillation catheter ablation

Michela Casella¹, Antonio Dello Russo¹, Eleonora Russo¹, Ghaliah Al-Mohani¹, Pasquale Santangeli², Stefania Riva¹, Gaetano Fassini¹, Massimo Moltrasio¹, Ester Innocenti¹, Daniele Colombo¹, Fabrizio Bologna¹, Gennaro Izzo¹, Joseph G. Gallinghouse², Luigi Di Biase², Andrea Natale², Claudio Tondo¹

¹Cardiac Arrhythmia Research Centre, Centro Cardiologico Monzino IRCCS, Milan, Italy
²Texas Cardiac Arrhythmia Institute at St. David Medical Center, Austin, Texas, USA

Abstract

Background: Our study aims to compare acute myocardial injury biomarker rise after atrial fibrillation ablation performed with different technologies.

Methods and Results: One hundred and ten patients were treated with pulmonary vein isolation with 4 different technologies: open-irrigated tip radiofrequency (RF) catheter in 35 patients (Group A), cryoballoon in 35 patients (Group B), visually guided laser balloon in 20 patients (Group C), open-irrigated tip RF catheter with contact-force-sensing technology in 20 patients (Group D). Post-procedure samples of cardiac troponin I (cTnI) and creatinine kinase-MB (CK-MB) were collected at 19 ± 3 h and 43 ± 3 h after ablation. At the first postprocedural sample, cTnI and CK-MB levels were found elevated in all 110 patients with a median value of 2.11 ng/mL and 8.95 ng/mL, respectively. Group B showed cTnI levels increased (median 5.96 ng/mL) compared to other groups (median Group A: 1.72 ng/mL, Group C: 1.54 ng/mL, Group D: 2.0 ng/mL; p < 0.001). Also CK-MB levels resulted higher in cryoablation (median 26.4 ng/mL) compared to other groups (median Group A: 6.40 ng/mL, Group C: 7.15 ng/mL, Group D: 6.50 ng/mL; p < 0.001). No significant association was observed between biomarker levels and recurrences of atrial fibrillation after a mean follow-up of 369 ± 196 days.

Conclusions: Highest markers for myocardial injury were observed in the cryoballoon group. It is possible that a longer delivery energy duration and other factors affecting lesion size resulted in higher amount of cardiac injury in cryoablation. The higher levels of cardiac biomarkers did not translate into a better outcome and its physiologic significance is unknown.

(Cardiol J 2014; 21, 5: 516–523)

Key words: cardiac biochemical markers, cardiac troponin I, creatinine kinase-MB, atrial fibrillation ablation, myocardial injury

Introduction

Pulmonary vein (PV) isolation has become the mainstay of interventional treatment of paroxysmal atrial fibrillation (AF) using catheter ablation [1]. Nevertheless, recovery of conduction between the PVs and the left atrium is relatively common after a successful initial procedure and it is strictly related to arrhythmia recurrence [2]. Permanent lesion creation has been the target of new technological improvements in ablation catheters. Initially the catheter tip irrigation allowed
to perform more extensive lesions; more recently these catheters have been strengthened with the assistance of contact-force-sensing technology to ensure a real-time, objective measure of contact force between the catheter tip and the beating heart wall during ablation. Furthermore, durability of lesion can be ameliorated by the utilization of new ablation catheter configurations, for example balloon catheters, or by the utilization of alternative sources of energy, such as cryothermal and laser energies [3, 4].

As several markers have been proven to be useful for diagnosis and evaluation of size of myocardial injury after acute ischemic episode, many authors tried to implement different biomarkers to evaluate and quantify the size of effective ablation lesions [5–18]. On one hand, previous studies have univocally shown humoral biomarkers for myocardial injury to be elevated after radiofrequency (RF) ablation, depending on the amount of energy delivered and the site of ablation [5]. On the other hand, contrasting data exist about myocardial injury biomarker trend after cryoablation procedures [6–9]. Furthermore, to date, no data have been available on these biomarkers after laser balloon ablation or after RF catheter ablation with the assistance of contact-force-sensing technology. In addition, it is unknown whether myocardial injury biomarker could predict persistent lesion at long-term follow-up and which is its role with regards to arrhythmia recurrence.

The purpose of this study was to compare cardiac troponin I (cTnI) and creatinine kinase isoenzyme MB (CK-MB) rise after AF ablation performed with 1 of 4 different technologies: conventional open-irrigated tip RF catheter, cryoballoon, visually guided laser balloon, irrigated tip RF catheter with contact-force-sensing technology. In addition, the biomarker rise was associated to clinical outcomes during follow-up.

Methods

Study population

We prospectively enrolled 110 consecutive patients suffering from drug refractory paroxysmal AF and admitted to our institution to perform catheter ablation. Paroxysmal AF was defined as episodes which converted spontaneously to sinus rhythm within 7 days or were sometimes terminated by electrical or pharmacological cardioversion within 48 h. Patients were randomized to PV isolation with conventional open-irrigated tip RF catheter (35 patients, Group A) or with cryoballoon catheter (35 patients, Group B), or with visually guided laser balloon (20 patients, Group C), and open-irrigated tip RF catheter with contact-force-sensing technology (20 patients, Group D). Only patients with normal baseline values for myocardial injury were included. We excluded patients with renal failure, myopathy, recent myocardial ischemia or clinical signs of infection.

Ablation procedure

Informed consent was obtained from all patients. Transseptal puncture was performed under fluoroscopic guidance only or with the adjunct of intracardiac echocardiography at physician’s discretion. After transseptal puncture, intravenous heparin was used to maintain an activated clotting time of 300–400 s. In all procedures, an esophageal temperature probe was used to monitor esophageal temperature changes during energy delivery. Energy delivery duration was also calculated and recorded.

Conventional open-irrigated tip RF catheter ablation

A single or double transseptal puncture was performed at physician’s discretion. For RF ablation, an open irrigated-tip catheter with a 3.5-mm-tip electrode (ThermoCool, Biosense Webster) was used in conjunction with a 3-dimensional electroanatomic mapping system (CARTO 3, Biosense Webster or NavX Fusion, St. Jude Medical). RF energy was delivered with power of up to 35 W and a maximum temperature of 43°C. Ablation was performed circumferentially, guided by a circular mapping catheter, near the antrum of each PV. The procedural endpoint was PV isolation as confirmed by the circumferential mapping catheter and pacing maneuvers (Lasso, Biosense Webster, Diamond Bar, CA, USA).

Cryoballoon ablation

A single or double transseptal puncture was performed according to the use of a conventional circumferential mapping catheter or the customized mapping catheter Achieve (Medtronic, Minneapolis, MN, USA). Positioning of the 28-mm or 23-mm diameter cryoballoon (Artic Front Medtronic, Minneapolis, MN, USA) was achieved using the guidewire and the 12.5 Fr-steerable sheath (Flexcath Medtronic Minneapolis, MN, USA). Only in 5 patients we adopted a second generation mapping catheter (Arctic Front Advance Cardiac CryoAblation Catheter System Medtronic, Minneapolis, MN, USA).
Because of a risk of right phrenic nerve palsy, while delivering cryoenergy to right PVs, a 6 F quadripolar catheter was positioned in the superior vena cava for phrenic nerve stimulation. After confirmation of PV occlusion by contrast injection, the 5-min freezing cycle was initiated (4-min with Arctic Front Advance). After 2 freezing cycles, PV isolation was assessed by circumferential mapping catheter.

**Visually guided laser balloon ablation**

Two transseptal punctures were performed for the ablation catheter and multipolar mapping catheter. After the dedicated 15 Fr deflectable sheath (Cardiofocus Inc.) was placed in the left atrium, the balloon catheter was inserted, inflated within the atrium, and sequentially positioned at each PV ostium. Energy delivery was performed with a power of 8.5–10 Watt for 20 s. Before delivery of energy to the right PVs, a pacing catheter was positioned within the superior vena cava for phrenic nerve stimulation. A Lasso catheter was used to interrogate each PV before and after ablation to assess whether electric isolation was achieved.

**Open-irrigated tip RF catheter ablation with contact-force-sensing technology**

Patients’ instrumentation was performed as in conventional procedures. All ablations were performed with a contact force sensing catheter (Tacticaht™ Endosense SA, or Contact Therapy™ Cool Path™ St. Jude Medical), which is a 7 Fr, open irrigated-tip catheter. The ablation catheter was connected through the splitter unit simultaneously to the RF generator and the force sensing base system. Energy delivery duration, mean contact force and force time integral (FTI) were also recorded and calculated.

**Blood sampling and Biomarker measurements**

Baseline blood tests were drawn at the time of hospital admission the day before the scheduled procedure in all patients (cTnI and CK-MB). Post-procedural samples were collected in the following 2 mornings after ablation.

Serum samples were processed at our hospital’s central laboratory facility. Within 30 min of collection, samples were centrifuged. cTnI was measured with the commercially available Access® AccuTnI™ assay (Beckman Coulter, Chaska, MN), CK-MB were tested by separate enzymatic commercially available test kits (CK-MB test). CK-MB and cTnI cut-off values (≥ 6.5 ng/mL, ≥ 0.1 ng/mL, respectively) were treated as pathologically increased.

**Postablation management and follow-up**

Regular follow-up consisted of outpatient clinic visits at 1, 3, 6, and 12 months after the procedure and included a detailed history, physical examination, 12-lead electrocardiogram, 24-h or 7-day Holter monitoring. Recurrence of AF post ablation is defined as a recurrence of AF more than 3 months following AF ablation. Episodes of atrial tachycardia or atrial flutter should also be classified as a “recurrence”. Recurrence rates were analyzed with a postprocedural blanking period of 3 months.

**Statistical analysis**

Data are reported as mean ± standard deviation. The distribution of variables was assessed by Kolmogorov-Smirnov test. Categorical variables, presented as counts and percentages, were compared in cross-tabulation tables by means of the Pearson $\chi^2$ test. The non-parametric Kruskal-Wallis and Wilcoxon tests were used to investigate differences among groups. Correlations of serum cTnI and CK-MB levels with procedural variables were performed using linear regression analysis (Pearson). These data were analyzed by the SPSS 20.0 statistical software (SPSS Italia, Inc., Florence, Italy). The threshold of statistical significance was set at a $p$ value of $< 0.05$.

**Results**

**Clinical characteristics**

The study population consisted of 110 consecutive patients referred for ablation of drug resistant AF (76% male, mean age 57.2 ± 11.3 years). Patients baseline characteristics did not differ among groups (Table 1).

**Procedural data**

The procedural endpoint of complete PV isolation was achieved in all 110 patients. In Group A patients, all PVs were successfully isolated with a mean of 27 ± 16 pulses with RF and a mean energy delivery duration of 2030 ± 695 s. No major adverse events were seen. In the cryoballoon group (Group B), a total of 133 PVs were targeted using the 28-mm balloon and 7 PVs using the 23-mm balloon. Mean energy delivery duration was 3062 ± 716 s with a mean of 11 ± 3 applications. Of 140 PVs, 128 (91%) were isolated using cryoballoon ablation alone, and 12 (8%) PVs were isolated using additional 3.5-mm irrigated-
Table 1. Patients’ baseline characteristics in the four groups.

<table>
<thead>
<tr>
<th></th>
<th>All patients (n = 110)</th>
<th>Group 1 (n = 35)</th>
<th>Group 2 (n = 35)</th>
<th>Group 3 (n = 20)</th>
<th>Group 4 (n = 20)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>57 ± 11</td>
<td>56 ± 13</td>
<td>58 ± 12</td>
<td>57 ± 8</td>
<td>58 ± 10</td>
<td>0.85</td>
</tr>
<tr>
<td>Male</td>
<td>84 (76%)</td>
<td>28 (80%)</td>
<td>23 (66%)</td>
<td>17 (85%)</td>
<td>16 (80%)</td>
<td>0.33</td>
</tr>
<tr>
<td>AF history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lone AF</td>
<td>44 (34%)</td>
<td>47 ± 41</td>
<td>43 ± 33</td>
<td>50 ± 30</td>
<td>36 ± 27</td>
<td>0.57</td>
</tr>
<tr>
<td>Hypertension</td>
<td>58 (53%)</td>
<td>22 (63%)</td>
<td>17 (49%)</td>
<td>9 (45%)</td>
<td>10 (50%)</td>
<td>0.53</td>
</tr>
<tr>
<td>LA size [mm]</td>
<td>42.1 ± 5.4</td>
<td>41.9 ± 5.5</td>
<td>41.5 ± 5.1</td>
<td>42.4 ± 5.1</td>
<td>43.2 ± 6.4</td>
<td>0.87</td>
</tr>
<tr>
<td>EF [%]</td>
<td>61.9 ± 7.3</td>
<td>62.0 ± 7.8</td>
<td>61.8 ± 7.1</td>
<td>61.7 ± 6.9</td>
<td>62.3 ± 7.4</td>
<td>0.99</td>
</tr>
<tr>
<td>CK [UI/L]</td>
<td>103 ± 69</td>
<td>111 ± 74</td>
<td>97 ± 82</td>
<td>105 ± 56</td>
<td>99 ± 69</td>
<td>0.97</td>
</tr>
<tr>
<td>CK-MB [ng/mL]</td>
<td>1.73 ± 0.92</td>
<td>1.64 ± 0.78</td>
<td>1.71 ± 0.97</td>
<td>1.89 ± 1.04</td>
<td>1.70 ± 0.89</td>
<td>0.93</td>
</tr>
<tr>
<td>cTnI [ng/mL]</td>
<td>0.03 ± 0.01</td>
<td>0.03 ± 0.02</td>
<td>0.02 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.98</td>
</tr>
</tbody>
</table>

Data are reported as mean ± standard deviation; AF — atrial fibrillation; LA — left atrium; EF — ejection fraction; CK — creatinine kinase; CK-MB — creatinine kinase-MB; cTnI — cardiac troponin I

Table 2. Procedural data in four different groups.

<table>
<thead>
<tr>
<th></th>
<th>All patients (n = 110)</th>
<th>Group 1 (n = 35)</th>
<th>Group 2 (n = 35)</th>
<th>Group 3 (n = 20)</th>
<th>Group 4 (n = 20)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electroanatomic mapping</td>
<td>79 (72%)</td>
<td>33 (94%)</td>
<td>10 (29%)</td>
<td>16 (20%)</td>
<td>20 (100%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Intracardiac echocardiography</td>
<td>32 (29%)</td>
<td>2 (6%)</td>
<td>6 (17%)</td>
<td>14 (70%)</td>
<td>10 (50%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Double transseptal puncture</td>
<td>37 (34%)</td>
<td>3 (9%)</td>
<td>13 (37%)</td>
<td>20 (100%)</td>
<td>1 (5%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Mean energy delivery duration [s]</td>
<td>2030 ± 695</td>
<td>3062 ± 716</td>
<td>2511 ± 1317</td>
<td>2069 ± 649</td>
<td>&lt; 0.0001</td>
<td></td>
</tr>
</tbody>
</table>

tip RF ablation catheter in 10 (28%) patients. No major complication occurred. In group C patients, there were a total of 78 PVs and one left common trunk; all PVs and the common trunk were targeted and successfully isolated. The average laser energy delivery duration was 2511 ± 1317 s. All PVs remained isolated after a minimum of 30 min post-ablation. There was only a case of procedural pericardial effusions. In group D patients, there were a total of 76 PVs and 2 left common trunks. All PVs isolation was obtained with a mean of 32 ± 13 RF applications and mean energy delivery duration of 2069 ± 649 s; the average contact force applied was 16 ± 8 g (range 2–44 g) while mean total FTI was 37036 ± 12527 g and mean FTI/RF application was 1371 ± 1427 g. No major complication occurred. Mean energy delivery duration differed significantly among four groups (p = 0.0001). In our series of 110 patients, 2 (1.8%) patients complained chest discomfort 24 h post ablation (1 patients post RF ablation, 1 patients post cryoballoon). None of the patients had electrocardiographic or echocardiographic changes suggesting coronary ischemia.

Table 2 lists the procedural details in all patients and in the four different groups.

**Postprocedural cTnI and CK-MB levels**

The cTnI levels and CK-MB were normal in all patients pre-ablation and increased in all patients after the procedure. The first post procedural blood tests were performed at about 15 ± 3 h after the beginning of RF ablation procedure. At the first postprocedural sample, cTnI levels were found elevated in all 110 patients with a median value of 2.11 ng/mL (0.20–19.85 ng/mL). Patients treated with cryoablation showed levels of cTnI significantly increased (5.96; range 2.59–19.85 ng/mL) compared to the other groups (Group A: 1.72; range 0.22–5.73 ng/mL; Group C: 1.54; range 0.20–4.13 ng/mL; Group D: 2.0; range 1.0–7.81 ng/mL) (p < 0.001) (Table 3, Fig. 1). Among cryoablation group, in patients undergoing cryoablation with second generation cryo catheter, we found elevated levels of cTnI (median 5.01 ng/mL), but we did not make any comparison because in this group we enrolled few patients. Also CK-MB levels were significantly elevated in 73 (66%) patients; in particular
elevated CK-MB values were found in 17 out of 35 (49%) Group A patients, in all 35 (100%) Group B patients, in 11 out of 20 (55%) Group C patients and in 10 out of 20 (50%) Group D patients (p < 0.001).

Patients treated with cryoablation showed significantly higher levels of CK-MB (26.4 ng/mL) compared to the others (Group A: 6.40 ng/mL, Group C: 7.15 ng/mL, and Group D: 6.50 ng/mL) (p < 0.001).

Second post procedural blood tests were performed at about 40 ± 3 h after the beginning of RF ablation procedure. cTnI levels were elevated in all 110 patients with a median value of 0.96 (range 0.07–10.06) ng/mL. Patients treated with cryoablation showed significantly higher levels of cTnI (2.46; range 0.72–10.06 ng/mL) compared to patients of Group A (0.80; range 0.08–2.94 ng/mL), Group C (0.69; range 0.07–1.45 ng/mL), and Group D (0.84; range 0.21–2.75 ng/mL) (p < 0.001) (Table 3).

Also CK-MB values were still above the level to detect myocardial injury in 19 (17%) patients; in particular CK-MB values were found elevated in 16 (46%) Group B patients, and in 3 (9%) Group A patients. Patients treated with cryoablation showed significantly higher levels of CK-MB (6.4 ng/mL) compared to patients of Group A (2.1 ng/mL), Group C (2.7 ng/mL), and Group D (2.48 ± 1.07 ng/mL) (p < 0.001). Myocardial injury biomarker values are summarized in Table 3.

**Clinical outcomes after AF ablation**

After 1 year of follow-up, 22 (20%) patients had clinical recurrences of AF; 7/35 (20%) patients

---

**Table 3.** Postprocedural cardiac troponin I (cTnI) and creatinine kinase-MB (CK-MB) levels in four different groups.

<table>
<thead>
<tr>
<th></th>
<th>All patients (n = 110)</th>
<th>Group 1 (n = 35)</th>
<th>Group 2 (n = 35)</th>
<th>Group 3 (n = 20)</th>
<th>Group 4 (n = 20)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>cTnI 1</td>
<td>2.11 (0.20–19.85)</td>
<td>1.72 (0.22–5.73)</td>
<td>5.96 (2.59–19.85)</td>
<td>1.54 (0.20–4.13)</td>
<td>2.0 (1.0–7.81)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>cTnI 2</td>
<td>0.96 (0.07–10.06)</td>
<td>0.80 (0.08–2.94)</td>
<td>2.46 (0.72–10.06)</td>
<td>0.69 (0.07–1.45)</td>
<td>0.84 (0.21–2.75)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>CK-MB 1</td>
<td>8.95 (2.30–106.3)</td>
<td>6.40 (2.3–14.4)</td>
<td>26.4 (9.40–106.3)</td>
<td>7.15 (3.60–11.30)</td>
<td>6.50 (2.3–19.30)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>CK-MB 2</td>
<td>3.2 (0.90–54.0)</td>
<td>2.1 (0.90–11.5)</td>
<td>6.4 (1.89–54.0)</td>
<td>2.7 (1.6–4.2)</td>
<td>2.2 (1.1–4.9)</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

Data are reported as median and range. All values are in ng/mL; cTnI 1 and CK-MB 1 refer to first postprocedural samples; cTnI 2 and CK-MB 2 refer to second postprocedural samples.
in Group A, 9/35 (25%) in Group B, 3/20 (15%) in Group C and 3/20 (15%) in Group D. Because of the frequency of clinical symptoms, 10/27 (37%) of these patients underwent repeat catheter ablation; 1 (4%) patient underwent electrical cardioversion; the remaining 16/27 (59%) patients were successfully treated with a strengthened pharmacological therapy. Redo procedures were performed after a postprocedural blanking period of 3 months in 2 patients in the Group A, in 4 patients in the Group B, in 2 patients in the Group C and in 2 patients in the Group D (p = 0.85).

**Analysis of biochemical markers with procedural and outcome data**

We also analyzed correlations of the levels of biochemical markers with the procedural data. There was a significant correlation between biomarker levels (first procedural sample) and longer energy delivery duration (for cTnI: \( r = 0.90, p = 0.001 \) and for CK-MB: \( r = 0.98, p = 0.001 \), respectively). The median value of cTnI and CK-MB (first post procedural sample) between AF recurrences group (22 patients) and no recurrences group (88 patients) was 2.1 ng/mL and 2.3 ng/mL for cTnI and 8.9 ng/mL and 9.1 ng/mL, respectively (Figs. 3, 4). Since these median values were similar in the two groups, we did not perform any further analysis in order to assess an association.

**Discussion**

In our study, we compare 4 different ablation catheter technologies and energy sources for AF ablation with regard to their effect on myocardial necrosis. We performed AF ablation with one of the following technologies: irrigated tip RF catheter, cryoballoon, laser balloon, irrigated tip RF catheter with contact-force-sensing technology. Myocardial injury biomarkers were elevated in all patients undergoing PV isolation without any signs of cardiac ischemia by serial 12-lead electrocardiograms. Higher values of post-procedural cTnI and CK-MB were found in patients undergone cryoablation in comparison to patients treated with RF ablation or laser balloon. We also found a correlation between the levels of biomarkers and energy delivery duration, with higher values of energy delivery duration in cryoballoon group.

**Previous studies**

As several markers have been proven to be of clinical utility for diagnosis and estimation of infarct size, many authors tried to implement different biomarkers to evaluate and quantify the extent of effective ablation lesions. First studies focused on RF lesion and it has been demonstrated that cTnI and cTnT are more sensitive and specific than CK-MB for the diagnosis of myocardial injury after RF ablation [5, 6]. It has also been showed that the rise of biomarkers and the extent of myocardial damage after RF catheter ablation depend on the number of RF pulses and site of ablation [12–16, 19]. A lower cTn level is expected after RF of focal area with few RF lesions. RF ablation of more myocardial tissue in the atria, such as in PV isolation, is expected to have much higher cTn levels [10–12, 20–25].
Previous clinical studies reported contrasting data, in the setting of AF ablation, on cardiac biomarkers levels after cryoballoon ablation compared to RF ablation [7, 13–19, 26]. Kühne et al. [7] reported higher post procedural cTnT levels in RF group vs. cryoballoon group. Siklody et al. [10] analyzed hs-TnT and showed no significant difference in RF ablation and cryoballoon ablation. Only 1 study [6] reported increase of TnT levels in patients treated with cryoballoon compared to those treated by RF ablation. Our finding that the cryoballoon resulted in a more pronounced myocardial injury is supported by 2 recent studies reporting higher cTnI levels after ablation with cryoballoon when comparing the PV ablation catheter using RF [19, 26]. In our study, the higher cTnI and CK-MB levels in cryoballoon group may be explained by longer energy delivery duration compared to the other groups. Previous AF ablation studies have found a correlation between levels of cTnT and RF delivery duration and cumulative RF energy [24, 27, 28], but no data exist regarding other energy sources. Apart from the energy delivery duration, other factors may contribute to higher degree of myocardial injury in cryoablation, as suggested by increased levels of biomarkers post ablation. In fact, larger lesion can be obtained in both cryo and open irrigation RF ablation, depending on the conditions under which the lesions are created. Electrode orientation, contact pressure and blood velocity are the main factors involved in lesion formation. During cryoablation larger contact surface between the cryoballoon catheter and the endocardial tissue and the complete occlusion of the PV minimizing convective warming of the local blood velocity may create larger lesions [10, 28].

Limitations of the study

Only 2 measurements of biomarkers of myocardial damage levels were performed at 15 ± 3 h and 43 ± 3 h and no serial measurements were performed to assess a peak in Tnl and CK-MB levels. Moreover, it was not possible to evaluate the kinetics of cTnI and CK-MB because of the lack of serial measurement. There are no published data about the release and kinetics of cTnI and CK-MB after catheter ablation with different energy sources so we cannot establish any comparison.

Conclusions

Compared to previous studies, we showed that cTnI and CK-MB are increased after PV isolation performed with 4 different ablation catheter technologies. Cardiac enzyme elevations are not specific for ischemia in the setting of chest pain after AF ablation. Higher values were found after cryoballoon ablation. It is possible that a longer delivery energy duration and other factors affecting lesion size resulted in higher amount of cardiac injury in cryoablation. However, the higher rise of cardiac biomarkers with cryoablation did not translate into a better clinical outcome and its physiologic significance is unknown.

Conflict of interest: C.T. has served as a member of the advisory board of Biosense Webster and has been a consultant for, and received lecture fees from, St. Jude Medical. A.N. has received compensation for belonging to the speakers’ bureau for St. Jude Medical, Boston Scientific, Medtronic, and Biosense Webster and has received a research grant from St. Jude Medical. A.N. is also a consultant for Biosense Webster. L.D.B. is a consultant for Hansen Medical and Biosense Webster. The other authors declare no significant relationships with industry.

References


